1. Home
  2. SKYA vs ELTX Comparison

SKYA vs ELTX Comparison

Compare SKYA & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SkyAI Inc. Common Stock

SKYA

SkyAI Inc. Common Stock

SELL

Current Price

$2.79

Market Cap

59.7M

Sector

Health Care

ML Signal

SELL

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

BUY

Current Price

$1.57

Market Cap

63.3M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
SKYA
ELTX
Founded
2017
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
59.7M
63.3M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
SKYA
ELTX
Price
$2.79
$1.57
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $13.67
AVG Volume (30 Days)
★ 1.8M
256.1K
Earning Date
11-16-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 39.29
EPS
N/A
★ N/A
Revenue
$204,120.00
★ $2,301,000.00
Revenue This Year
$35,369.33
N/A
Revenue Next Year
$9.94
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.91
$1.47
52 Week High
$2.83
$16.00

Technical Indicators

Market Signals
Indicator
SKYA
ELTX
Relative Strength Index (RSI) 75.68 20.20
Support Level $1.60 N/A
Resistance Level N/A $1.97
Average True Range (ATR) 0.19 0.13
MACD 0.08 0.00
Stochastic Oscillator 98.37 0.00

Price Performance

Historical Comparison
SKYA
ELTX

About SKYA SkyAI Inc. Common Stock

SkyAI Inc is developing financial technology platforms focused on users in emerging markets. Its operations include the use of stablecoin-based payment infrastructure and artificial intelligence (AI) technologies to provide financial access, educational tools, and data analysis services for users in Asia, Latin America, and Africa. The company's platform will utilize the Solana blockchain network to support digital asset and on-chain data applications.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: